Regional and national burden of prostate cancer: incidence, mortality, years of life lost, and disability-adjusted life years, in Mexico and Latin America from 1990 to 2019.

PURPOSE: Prostate cancer (PC) is the second leading cause of cancer and the fifth cause of cancer-related death. This manuscript aims to determine the incidence, mortality, and Disability Adjusted Life Years (DALYs) trends of PC in the last 30 years in Latin America and Mexico. METHODS: We performed a cross-sectional analysis of a publicly available data set. Data regarding the burden of prostate cancer in 20 Latin-American countries, and the 32 states of Mexico, were retrieved from the Global Burden of Disease Study 2019. Collected information included incidence and mortality rates (per 100,000), as well as the DALYs as absolute numbers and rates (per 100,000) and the annual rates of change in rates from 1990 to 2019. RESULTS: In Latin America in males aged 55 years or older, the mean incidence rate was 344 cases per 100,000. The number of deaths attributable to prostate cancer observed was 67,110 and the mean mortality rate was 210 per 100,000. The overall burden of disease was 1,120,709 DALYs and the contribution of years of life lost (YLL) was 91.7% ([Formula: see text] = 1,027,946). Mexico presented an incidence rate (279.6) and mortality (99.1) rate (per /100 thousand). In Mexico, 13 states had a DALYs' rate above the national mean (883 per 100,000) and the highest burden (1360 DALYs/100,000) were documented in the state of Guerrero (Southwestern Mexico). CONCLUSION: Only two Latin-American countries (Brazil and Colombia) and eight states of Mexico showed a decreased trend about the rate of change of DALYs in the last 30 years.

Animal models of kidney iron overload and ferroptosis: a review of the literature.

In recent years, it has been identified that excess iron contributes to the development of various pathologies and their complications. Kidney diseases do not escape the toxic effects of iron, and ferroptosis is identified as a pathophysiological mechanism that could be a therapeutic target to avoid damage or progression of kidney disease. Ferroptosis is cell death associated with iron-dependent oxidative stress. To study the effects of iron overload (IOL) in the kidney, numerous animal models have been developed. The methodological differences between these models should reflect the IOL-generating mechanisms associated with human IOL diseases. A careful choice of animal model should be considered for translational purposes.

Insight into the Burden of Malignant Respiratory Tumors and their Relationship with Smoking Rates and Lead Contamination in Mexico.

We aimed to report the results from the Global Burden of Disease Study 2019 related to respiratory malignant tumors (tracheal, bronchial, and lung) in Mexico. We also evaluated the relationship between the burden of these neoplasms and the proportion of daily smokers and total lead emissions in 2019. A cross-sectional analysis of ecological data was performed. The burden of these tumors was 152,189 disability-adjusted life-years (DALYs), and years of life lost (YLL) contributed to 99% of them. The highest DALYs rates (per 100,000) were observed in the states of Sinaloa, Chihuahua, Baja California Sur, Sonora, and Nayarit. We documented a linear relationship between the DALYs rates and the prevalence of daily smokers (ß = 8.50, 95% CI 1.58-15.38) and the total lead emissions (tons/year: ß = 4.04, 95% CI 0.07-8.01). If later replicated, our study would provide insight into the major relevance of regulating tobacco use and the activities associated with the production of lead dust and other hazardous contaminants.

Variaciones por edad y sexo en las tendencias de infección por el virus de la inmunodeficiencia humana en el Instituto Mexicano del Seguro Social: 2003-2017 / Gender and age-related variations in human immunodeficiency virus infection trends at the Mexican Institute of Social Security: 2003-2017

Resumen Introducción: Hacer el diagnóstico y tratar a portadores del virus de la inmunodeficiencia humana ha llevado a identificar mayor prevalencia de esa infección y, por lo tanto, de un mayor riesgo de transmisión de este virus. Objetivo: Conocer la tendencia en México de los nuevos casos de portadores de infección por el virus de la inmunodeficiencia humana en el Instituto Mexicano del Seguro Social (IMSS) en el periodo 2003-2017. Métodos: Se analizaron pacientes asegurados en el IMSS. Se obtuvieron datos de 42 181 casos recién diagnosticados y se analizaron las variaciones relacionadas con el sexo y la edad. Se obtuvieron las tasas estandarizadas por edad por 100 000 personas. Resultados: El cambio porcentual anual promedio más alto en hombres se documentó en adolescentes varones (13.0, IC 95 % = 9.9, 16.1). Se registraron tendencias heterogéneas en las mujeres, con una disminución total significativa (-2.2, IC 95 % = -3.4, -1.0), pero también se observaron tendencias crecientes en algunos grupos. Conclusiones: Los resultados sugieren que en el IMSS, la epidemia de la inmunodeficiencia humana adquirida se concentra en hombres, con tendencia creciente particularmente en adolescentes.

Abstract Introduction: Diagnosing and treating human immunodeficiency virus carriers has led to the identification of a higher prevalence of said infection and, therefore, of a higher risk of transmission of the virus. Objective: To find out the trend of new cases of human immunodeficiency virus infection carriers at the Instituto Mexicano del Seguro Social (IMSS) in Mexico within the 2003-2017 period. Methods: Patients affiliated to the IMSS were analyzed. Data from 42,181 newly-diagnosed cases were collected, with variations related to gender and age being observed. Age-standardized rates per 100,000 population were obtained. Results: The highest mean annual percentage change in males was documented in adolescents (13.0, 95% CI = 9.9, 16.1). Heterogeneous trends were recorded for women, with a significant overall decrease (-2.2, 95% CI = -3.4,-1.0), but growing trends were also observed in some groups. Conclusions: Our results suggest that the human immunodeficiency epidemic in patients cared for at the Instituto Mexicano del Seguro Social is concentrated in males, with a growing trend particularly in adolescents.

Independent risk factors of COVID-19 pneumonia in vaccinated Mexican adults.

OBJECTIVES: To evaluate host factors associated with the risk of coronavirus disease 2019 (COVID-19) pneumonia in vaccinated adults. METHODS: A cohort study was conducted in Mexico, and data from 1607 adults with confirmed illness, with a positive history of COVID-19 vaccination, were analyzed. Risk ratios (RR) and 95% confidence intervals (CI) were computed as a measure of the significance of the associations between putative risk factors and the prevalence of COVID-19 pneumonia in vaccinated subjects. RESULTS: The overall risk of pneumonia was 1.98 per 1000 person-days. In the multiple regression analysis, older subjects, those with a history of smoking (current), obesity, and type 2 diabetes mellitus were at increased risk of pneumonia. CONCLUSIONS: Our results suggest that the effectiveness of COVID-19 vaccines may be reduced in a subset of adults who are older aged, smokers, obese, or have type 2 diabetes mellitus.

Patient and treatment delays among Mexican women with breast cancer before and after the Seguro Popular / Retrasos del paciente y del tratamiento en mujeres mexicanas con cáncer de mama antes y después del Seguro Popular

Abstract: Objective: To assess whether the Catastrophic Health Expenditures Fund (FPGC, Spanish acronym) was associated with delays in seeking medical care and in starting treatment. Materials and methods: We conducted a before and after cross-sectional study. We included 266 women with breast cancer (BC) diagnosis treated during the last three years before the hospitals received the FPGC and 309 women treated in the following three years after the fund was received by the accredited hospitals. Results: After adjusting for potential confounders, we found no association between the FPGC and delay in seeking medical care or between the FPGC and the treatment delay. Conclusions: The FPGC initiative reduced neither the delay in seeking breast cancer medical care for breast cancer nor the treatment delay.

Resumen: Objetivo: Evaluar si el Fondo de Protección contra Gastos Catastróficos en Salud (FPGC) se asoció con retrasos en la búsqueda de atención médica e inicio del tratamiento. Material y métodos: Estudio transversal antes y después, que incluyó 266 mujeres con diagnóstico de cáncer de mama (CM) tratadas durante los últimos tres años previos a que los hospitales recibieran el FPGC y 309 mujeres tratadas en los siguientes tres años posteriores a que los hospitales recibieran el fondo. Resultados: El FPGC no se asoció con el retraso en la búsqueda de atención médica ni con el retraso del inicio del tratamiento. Conclusiones: El FPGC no redujo el retraso en la búsqueda de atención médica por CM ni el retraso del inicio del tratamiento.

Detección de hígado graso no alcohólico en niños con sobrepeso y obesidad / Detecting non-alcoholic fatty liver in children with owerweight and obesity

Introducción: la enfermedad del hígado graso no alcohólico (EHGNA) tiene graves implicaciones para la salud y, asociada a la epidemia de obesidad, es una tendencia creciente. Objetivo: detectar la presencia de hígado graso en niños con sobrepeso y obesidad, así como evaluar los factores asociados con una mayor posibilidad de presentar un resultado positivo en la detección. Metódos: se realizó un estudio de tipo transversal en una unidad médica del segundo nivel de atención médica en el que fueron reclutados 102 niños. Los niveles séricos de alanina aminotransferasa (ALT) fueron cuantificados y se realizaron ecografías hepáticas. Modelos de regresión logística múltiple fueron utilizados para evaluar los factores asociados con la presencia de EHGNA (infiltración grasa en la ecografía y ALT > 52U/L para niños y > 44 U/L para niñas). Resultados: la prevalencia de EHGNA fue del 10,8%. En el análisis multivariante, una relación entre cintura y cadera ≥ 1 se asoció con una mayor posibilidad de EHNGA (razón de momios (RM) = 4.96, IC del 95%: 1.17 - 20.90). Conclusiones: nuestros hallazgos indican que uno de cada diez niños sobrepeso y obesidad tiene datos sugestivos de EHGNA y está en riesgo de presentar sus consecuencias para la salud.

Background: Non-alcoholic fatty liver disease (NAFLD) has serious health implications and upward trends of the disease, accompanied by the obesity epidemic worldwide. Objective: To screen for fatty liver in overweight and obese children and evaluate the factors associated with an increased likelihood of presenting a positive-screen result. Methods: In a cross-sectional study, 102 children were recruited at a secondary care medical unit. Serum alanine aminotransferase (ALT) levels were quantified and hepatic ultrasounds were performed; multiple logistic regression models were used to evaluate factors associated with the increased odds of presenting with NAFLD (fatty infiltration on ultrasound and ALT > 52 U/L for boys and > 44 U/L for girls). Results: The overall prevalence of NAFLD was 10.8%. In multivariate analysis, a waist-to-hip ratio ≥ 1 was associated with increased odds of screening positive for NAFLD (odds ratio (OR) = 4.96, 95% CI 1.17-20.90). Conclusions: Our findings indicate that one out of ten children with overweight or obesity has data suggestive of NAFLD and is at risk of presenting its consequences on health.

Improve cognitive impairment using mefenamic acid non-steroidal anti-inflammatory therapy: additional beneficial effect found in a controlled clinical trial for prostate cancer therapy.

Inflammation is an essential component of prostate cancer (PCa), and mefenamic acid has been reported to decrease its biochemical progression. The current standard therapy for PCa is androgen deprivation therapy (ADT), which has side effects such as cognitive dysfunction, risk of Alzheimer's disease, and dementia. Published results of in vitro tests and animal models studies have shown that mefenamic acid could be used as a neuroprotector. Objective: Examine the therapeutic potential of mefenamic acid in cognitive impairment used in a controlled clinical trial. Clinical trial phase II was conducted on patients undergoing ADT for PCa. Two groups of 14 patients were included. One was treated with a placebo, while the other received mefenamic acid 500 mg PO every 12hrs for six months. The outcome was evaluated through the Mini-Mental State Examination (MMSE) score at six months. At the beginning of the study, both groups had similar MMSE scores (mefenamic acid vs. placebo: 26.0±2.5 vs. 27.0±2.6, P=0.282). The mefenamic acid group improved its MMSE score after six months compared with the placebo group (27.7±1.8 vs. 25.5±4.2, P=0.037). Treatment with mefenamic acid significantly increases the probability of maintained or raised cognitive function compared to placebo (92% vs. 42.9%, RR=2.2, 95% CI: 1.16-4.03, NNT=2.0, 95% CI: 1.26-4.81, P=0.014). Furthermore, 42.9% of the placebo group patients had relevant cognitive decline (a 2-point decrease in the MMSE score), while in patients treated with mefenamic acid, cognitive impairment was not present. This study is the first conducted on humans that suggests that mefenamic acid protects against cognitive decline.

Erectile dysfunction, lower urinary tract symptoms, and quality of life in men above 50 years of age. / Disfunción eréctil, síntomas del tracto urinario inferior y calidad de vida en varones mayores de 50 años.

BACKGROUND: Lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) are relevant health problems worldwide, especially in men 50 years of age and older. With the increase in life expectancy, their prevalence is expected to rise in the coming years. AIM: To estimate the prevalence of LUTS and ED in adults 50 years of age and older and evaluate their relation to quality of life. MATERIALS AND METHODS: An analytic cross-section-al study was conducted through a personal interview with the participants. Erectile dysfunction (IIEF-5), prostate symptom (IPSS), and quality of life (EuroQoL) questionnaires were employed. The frequency and grade of LUTS and ED were evaluated and correlated with health-related quality of life perception in 300 men above 50 years of age. Summary measures were calculated. The association of LUTS and ED with quality of life was evaluated with prevalence odds ratios (ORs) and 95% confidence intervals (CIs), calculated using unconditional logistic regression models. RESULTS: Information on 300 subjects was analyzed. The general prevalence of LUTS and ED was 88.3% and 81.7%, respectively. Quality of life was classified as very poor - regular (≤ 60 points) in 18.3% of the subjects. In the multiple analysis, the presence of moderate LUTS (OR = 5.27, 1.08 - 9.73) or severe LUTS (OR = 7.05, 1.84-10.34) was associated with an increase in the possibility of presenting with a lower quality of life. CONCLUSION: Our findings suggest that erectile dysfunction and prostate symptoms were frequent events in the population studied, as was a low perception of quality of life. The opportune and efficacious treatment of those pathologies can potentially improve the individual and social dynamics of the persons affected.

ANTECEDENTES: A nivel mundial, los Síntomas del Tracto Urinario Inferior (STUI) y la Disfunción Eréctil (DE) son un problema relevante de salud pública, especialmente en varones de 50 o más años. Se espera que con el aumento de la esperanza de vida, su prevalencia se incrementa aún más en los próximos años. OBJETIVO: Estimar la prevalencia de los STUI y DE en adultos de 50 años o más de edad y evaluar su relación con la calidad de vida.MATERIAL Y MÉTODOS: Se realizó un estudio transversal analítico a través de una entrevista personal con los participantes. Se emplearon los cuestionarios de disfunción eréctil (IIEF-5), de síntomas prostáticos (IPSS) y la calidad de vida (EuroQoL). Se evaluó la frecuencia y grados de los Síntomas del Tracto Urinario Inferior y Disfunción Eréctil y se correlacionó con la percepción de Calidad de Vida relacionada a la salud en 300 varones mayores de 50 años. Se estimaron medidas sumarias. La asociación de STUI y DE con la calidad de vida fue evaluada con razones de momios (RM) prevalentes e intervalos de confianza (IC) del 95% estimados con modelos de regresión logística no condicional. RESULTADOS: Información de 300 sujetos fue analizada. La prevalencia general de STUI y DE fue 88,3% y 81,7% respectivamente. El 18,3% de los sujetos fueron clasificados como con una calidad de vida muy mala ­ regular (≤ 60 puntos). En el análisis múltiple, la presencia de STUI moderados (RM = 5,27, 1,08 ­ 9,73) o severos (RM = 7,05, 1,84 -10,34) se asoció con un incremento en la posibilidad de presentar una menor calidad de vida.CONCLUSIÓN: Nuestros hallazgos sugieren que la disfunción eréctil y los síntomas prostáticos son eventos frecuentes en la población estudiada, al igual que una baja percepción de la calidad de vida. La atención oportuna y eficaz de estas patologías puede potencialmente mejorar la dinámica individual y social de los sujetos afectados.

Patient and treatment delays among Mexican women with breast cancer before and after the Seguro Popular.

OBJECTIVE: To assess whether the Catastrophic Health Expenditures Fund (FPGC, Spanish acronym) was associated with delays in seeking medical care and in starting treatment. MATERIALS AND METHODS: We conducted a before and after cross-sectional study. We included 266 women with breast cancer (BC) diagnosis treated during the last three years before the hospitals received the FPGC and 309 wo-men treated in the following three years after the fund was received by the accredited hospitals. RESULTS: After adjusting for potential confounders, we found no association between the FPGC and delay in seeking medical care or between the FPGC and the treatment delay. CONCLUSIONS: The FPGC initiative reduced neither the delay in seeking breast cancer medical care for breast cancer nor the treatment delay.

Characterisation of palliative sedation use in inpatients at a medium-stay palliative care unit.

BACKGROUND: Palliative sedation has been used to refer to the practice of providing symptom control through the administration of sedative drugs. The objective of this article was to characterise palliative sedation use in inpatients at a medium-stay palliative care unit. MATERIAL AND METHODS: A cross-sectional study was conducted on 125 randomly selected patients (aged 15 or older) who had died in 2014. The Palliative Performance Scale was used to evaluate the functional status. RESULTS: Palliative sedation was documented in 34.4% of the patients and midazolam was the most commonly used sedative agent (86.0%). More than half (53.5%) of those who recieved sedation presented with delirium. Liver dysfunction was more frequent in the sedated patients (p=0.033) and patients with heart disease were less likely (p=0.026) to be sedated. CONCLUSION: Palliative sedation is an ethically accepted practice. It was commonly midazolam-induced, and differences were documented, among sedated and non-sedated patients, in terms of liver dysfunction and heart disease.

Disability-Adjusted Life Years for Cancer in 2010⁻2014: A Regional Approach in Mexico.

The disability-adjusted life years (DALYs) were used to estimate the regional (state of Colima, Mexico) cancer burden in 2010⁻2014. The years of life lost (YLL) were estimated with mortality data and years lived with disability (YLD) using incidence data. The DALYs were calculated as the arithmetic addition of YLL and YLD. Sex and cancer site-specific estimations were made and DALY rates were used to identify the leading causes of disease burden. Data from 2532 deaths were analyzed and, for all malignant tumors combined, 18,712.9 DALYs and 20,243.3 DALYs were estimated in males and females respectively. The overall contribution of YLL in DALY estimates was higher among females (93.7% vs. 87.4%). Age-standardized DALY rates (and 95% confidence intervals, CI) per 100,000 inhabitants were used to rank the leading causes of disease burden and, among males, malignant tumors from the prostate, lower respiratory tract, and colon and rectum accounted the highest rates (45.7, 95% CI 32.7⁻59.3; 37.6, 95% CI 25.7⁻49.9; and 25.9, 95% CI 16.0⁻36.1 DALYs). Breast, cervix uteri, and lower respiratory tract cancer showed the highest burden in females (66.0, 95% CI 50.3⁻82.4; 44.4, 95% CI 31.5⁻57.7; and 20.9, 95% CI 12.0⁻30.0 DALYs). The present study provides an indication of the burden of cancer at the regional level, underscoring the need to expand cancer prevention, screening, and awareness programs, as well as to improve early diagnosis and medical treatment.

Clinical markers associated with acute laboratory-confirmed Dengue infection: results of a national epidemiological surveillance system / Marcadores clínicos asociados con la infección de Dengue confirmada por laboratorio: resultados del sistema nacional de vigilancia epidemiológica

ABSTRACT Objective To evaluate the association of several clinical markers with acute laboratory-positive Dengue Virus infection. Methods A hospital-based case-control study was conducted in the state of Colima, Mexico, by using information from the National System of Epidemiological Surveillance (Sistema Nacional de Vigilancia Epidemiológica [SINAVE]) for Dengue. Data from 2 732 cases and 2 775 frequency-matched controls were analyzed. Odds Ratio (OR) and the 95 % Confidence Interval (CI), estimated by means of logistic regression models, were used. Results The presence of skin rash (OR=1,7; 95 % CI 1,5-2,1), persisting vomiting (OR=1,8; 95 % CI 1,5-2,3) and increased capillary fragility (petechiae, ecchymosis, hematoma or positive tourniquet test; OR=1,8; 95 % CI 1,2-2,6) were associated with laboratory-positive infection. Conclusions Three clinical markers were significantly associated with an increased risk of acute laboratory-confirmed dengue infection. These findings would support accurate and timely diagnosis of dengue in laboratory-limited settings.(AU)

RESUMEN Objetivo Evaluar la asociación de distintos marcadores clínicos con la infección por virus de Dengue, confirmada por laboratorio. Métodos Se condujo un estudio hospitalario de casos y controles, en el estado de Colima, México, usando información del Sistema Nacional de Vigilancia Epidemiológica (SINAVE) para dengue. Se analizó la información de 2 732 casos y 2 775 controles de frecuencia compatible/pareada. Se utilizó la Razón de Momios (RM) y el Intervalo de Confianza de 95 % (IC), estimado con modelos de regresión logística. Resultados La presencia de exantema (OR=1,7; 95 % CI 1,5-2,1), vómito persistente (OR=1,8; 95 % CI 1,5-2,3) y fragilidad capilar aumentada (petequias, equimosis, hematomas o prueba del torniquete positiva; OR=1,8; 95 % CI 1,2-2,6) se asociaron con la infección por dengue confirmada por laboratorio. Conclusiones Tres marcadores clínicos se asociaron significante con un riesgo incrementado de la infección aguda por dengue confirmada por laboratorio. Estos hallazgos pueden apoyar al preciso y oportuno diagnóstico de la infección en sitios con acceso limitado a laboratorios.(AU)

Persistent arthralgia and related risks factors in laboratory-confirmed cases of Chikungunya virus infection in Mexico / Artralgia persistente y factores de riesgos relacionados en casos confirmados por laboratorio de infección por el virus del Chikunguña en México / Artralgia persistente e fatores de riscos relacionados em casos confirmados em laboratório de infecção pelo vírus Chikungunya no México

ABSTRACT Objective To estimate the cumulative incidence of persistent arthralgia at 6 months from acute Chikungunya virus (CHIKV) infection and to evaluate the association of clinical markers with the risk of long-term arthralgia. Methods This multicenter retrospective cohort study was conducted in the Mexican state of Colima. A total of 136 individuals aged 15 years and older with serologically confirmed CHIKV infection were enrolled. Participants were interviewed at 6 months from the onset of symptoms, and self-reported persistent arthralgia (PA) was the main binary outcome. A self-report numeric rating scale (NRS) ranging from 0 to 10 was used to estimate the severity of articular pain. Results The cumulative incidence of PA was 41.9%. Severe pain (NRS ≥ 7) presented in 36.8% of participants with PA. In multiple analysis, individuals aged 40 years and older (risk ratio (RR) = 1.60; 95% confidence interval (CI), 1.03–2.48) and those with articular pain at 3 months post-infection (RR = 3.95; 95% CI, 1.95–8.01) had a significantly increased risk of PA at 6 months from CHIKV infection. Conclusions To the best of our knowledge, this is first report of a CHIKV-associated long-term outcome in Mexico, where the incidence of the infection has been high. This is also the first study in Latin America evaluating several factors associated with the risk of PA. Our findings may be useful in health care settings to stratify the risk of chronic arthralgia secondary to CHIKV infection and to identify patients who would benefit clinically from early medical intervention.

RESUMEN Objetivo Calcular la incidencia acumulada de artralgia persistente en los 6 meses siguientes a la infección aguda por el virus del Chikunguña y evaluar la asociación entre los marcadores clínicos y el riesgo de artralgia a largo plazo. Método Este estudio de cohortes multicéntrico y retrospectivo se condujo en el estado mexicano de Colima con la participación de un total de 136 personas de al menos 15 años de edad con infección aguda por el virus de Chikunguña serológicamente confirmada. Se entrevistó a los participantes en los seis meses posteriores al inicio de los síntomas, y la artralgia persistente autonotificada fue el principal resultado dicotómico. Para calcular la gravedad del dolor articular, se empleó una escala de clasificación numérica, en que el participante puntuaba la gravedad del dolor articular de 0 a 10. Resultados La incidencia acumulada de artralgia persistente fue de 41,9%. De los participantes con artralgia persistente, 36,8% presentaron un dolor intenso (igual o mayor a 7 en la escala de clasificación numérica). En varios análisis, las personas de al menos 40 años de edad (razón de riesgo [RR] = 1,60; intervalo de confianza [IC] de 95%, 1,03–2,48) y las personas que experimentaban dolor articular en los tres meses posteriores a la infección (RR = 3,95; IC de 95%, 1,95–8,01) tenían un riesgo significativamente mayor de padecer artralgia persistente en los seis meses siguientes a la infección aguda por el virus del Chikunguña. Conclusiones En la medida de nuestro conocimiento, este es el primer informe acerca de un resultado a largo plazo asociado a la infección aguda por el virus del Chikunguña en México, donde se ha registrado una incidencia alta de la infección. También es el primer estudio en el que se evalúan varios factores asociados al riesgo de artralgia persistente realizado en América Latina. Nuestros resultados pueden ser útiles en los establecimientos de atención de salud para estratificar el riesgo de padecer artralgia crónica subsecuente a la infección aguda por el virus de Chikunguña e identificar a los pacientes que se beneficiarían clínicamente de una intervención médica temprana.

RESUMO Objetivo Calcular a incidência acumulada de artralgia persistente após 6 meses de infecção aguda pelo vírus Chikungunya (CHIKV, sigla em inglês) e avaliar a associação de marcadores clínicos com o risco de artralgia a longo prazo. Métodos Este estudo de coorte retrospectivo e multicêntrico foi realizado no estado mexicano de Colima. Um total de 136 indivíduos com idade a partir de 15 anos e infecção pelo CHIKV confirmada por sorologia foram incluídos. Os participantes foram entrevistados 6 meses após o surgimento dos sintomas. O desfecho binário principal foi artralgia persistente (AP) autorrelatada. Uma escala numérica autorrelatada de 0 a 10 foi utilizada para calcular a gravidade da artralgia. Resultados A incidência acumulada de AP foi 41,9%. Dor intensa (≥ 7 na escala numérica) foi relatada por 36,8% dos participantes com PA. A análise múltipla revelou risco significantemente elevado de AP 6 meses após infecção pelo CHIKV nos indivíduos com idade igual ou superior a 40 anos (razão de risco (RR) = 1,60; intervalo de confiança (IC) de 95% = 1,03–2,48) e naqueles com dor articular 3 meses após a infecção (RR = 3,95; IC 95% = 1,95–8,01). Conclusões Até onde sabemos, este é o primeiro relato de um desfecho a longo prazo associado à infecção por CHIKV no México, país onde a incidência desta infecção foi elevada. Este é também o primeiro estudo realizado na América Latina a avaliar vários fatores associados com o risco de AP. Nossos achados talvez sejam úteis para estratificação do risco de artralgia crônica secundária à infecção pelo CHIKV e para identificação de pacientes nos quais intervenção médica precoce poderia ser benéfica do ponto de vista clínico.

Association between rs2981582 polymorphism in the FGFR2 gene and the risk of breast cancer in Mexican women.

BACKGROUND AND AIMS: The rs2981582 single nucleotide polymorphism in the fibroblast growth factor receptor 2 gene has been consistently associated with an increased risk of breast cancer. We evaluated the effect of rs2981582 polymorphism in the FGFR2 gene on the risk of breast cancer and its interaction with non-genetic risk factors. METHODS: A population-based case-control study was conducted in Mexico. Data from 687 cases and 907 controls were analyzed. RESULTS: The T allele of the rs2981582 polymorphism was associated with an increased risk of breast cancer (ORper allele = 1.24, 95% CI 1.06-1.46). There was also an interaction between this polymorphism and alcohol consumption (p = 0.043). The effect of alcohol consumption on the risk of breast cancer varied according to the allelic variants of the rs2981582 polymorphism in the FGFR2 gene: OR = 3.97 (95% CI 2.10-7.49), OR = 2.01 (95% CI 1.23-3.29) and OR = 1.21 (95% CI 0.48-3.05) for genotypes CC, CT and TT, respectively. CONCLUSIONS: This is the first study exploring the association between rs2981582 polymorphism in the FGFR2 gene and breast cancer risk in Mexican women. The interaction found may be of great public health interest because alcohol consumption is a modifiable breast cancer risk factor. Therefore, replication of this finding is of foremost importance.

Moderate-intensity physical activity ameliorates the breast cancer risk in diabetic women.

OBJECTIVE: To evaluate the association between self-reported diabetes and the risk of breast cancer (BC) and its interaction with moderate-intensity physical activity in pre- and postmenopausal Mexican women. RESEARCH DESIGN AND METHODS: A population-based case-control study was conducted using 1,000 incident case subjects and 1,074 control subjects. Blood samples and information on health, diet, physical activity, and anthropometric measurements were obtained. RESULTS: The association between diabetes and BC risk decreased with increasing tertiles of moderate-intensity physical activity (odds ratio [OR] = 4.9 [95% CI 2.3-10.8]; 3.0 [1.3-6.9]; and 1.0 [0.1-9.2], respectively, for each tertile) (test for interaction = 0.04). Compared with the women in the lowest tertiles, increased risk was observed in those premenopausal women with the highest serum C-peptide, IGF-1, and IGF-1 binding protein 3 levels. CONCLUSIONS: Moderate-intensity physical activity can substantially ameliorate the increased BC risk in diabetic women.